News Digging > Editor's Picks > ACC23: Bayer and J&J's Xarelto reduces ischemia risk for PAD patients after revascularization surgery
ACC23: Bayer and J&J's Xarelto reduces ischemia risk for PAD patients after revascularization surgery
ACC23: Bayer and J&J's Xarelto reduces ischemia risk for PAD patients after revascularization surgery,When added to aspirin, Bayer and J&J’s Xarelto reduced the risk of ischemia by 33% in patients with PAD who had revascularization surgery.

ACC23: Bayer and J&J's Xarelto reduces ischemia risk for PAD patients after revascularization surgery

When added to aspirin, Bayer and J&J’s Xarelto reduced the risk of ischemia by 33% in patients with PAD who had revascularization surgery.